The PCBC-3 functions by explosively rupturing a double-walled internal canister containing liquefied cryogenic compound held at approximately -196°C under significant pressure. The detonation is not primarily chemical — the explosive charge is minimal, serving only to rupture the canister and propel the cryogenic agent outward in a radial burst. The liquid compound flash-vaporizes on contact with ambient air, creating a localized temperature drop of 80–120°C within the dispersal radius in under 0.4 seconds. Materials and tissues within the primary zone experience extreme thermal shock: metals become brittle, polymers shatter, biological tissue freezes and fractures under mechanical stress.

The PCBC-3's tactical signature is defined by what happens after the initial burst. Unlike heat-based charges, the cryogenic effect persists in the environment for 15–40 seconds depending on ambient temperature and ventilation — the area remains lethally cold long after detonation, and surfaces remain structurally compromised. Armor plating hit by the burst loses significant tensile strength for the duration of the cold window, making it vulnerable to follow-up kinetic impacts that it would normally deflect. Security barriers, reinforced doors, and vehicle hulls can be rendered brittle and then breached with tools or impacts that would otherwise be completely ineffective.

Helix Biosystems developed the PCBC-3 under a cryogenic medical research framework — the same technology used for rapid-freeze tissue preservation in trauma response units. The weaponized variant was not an official Helix product; it emerged from an internal R&D division that was quietly licensing the core compression technology to a third-party arms developer. When the connection became public in 2198, Helix's official position was that the licensing agreement had been unauthorized. Three division heads were terminated. The PCBC-3 continued to circulate.